CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)
"CLO25-074: Outcomes to Immune Checkpoint Inhibitors (ICIs) According to Programmed Death-Ligand 1 (PD-L1) Levels in KRAS-, KEAP1-, STK11-Mutant Lung Squamous Cell Carcinoma (LSCC)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Weston He
- Misty Dawn Shields (ORCID: https://orcid.org/0000-0002-7904-5062)
- Justin W. Shi
- Julian A. Marin‐Acevedo (ORCID: https://orcid.org/0000-0001-7067-173X)
- Mya Tran (ORCID: https://orcid.org/0000-0001-6697-5992)
- Ahmad Karkash
- Yan Han (ORCID: https://orcid.org/0000-0003-2279-9127)
Institutions
- Indiana University Health (US)
- Indiana University Indianapolis (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7142
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00